ImmuPharma (GB:IMM) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ImmuPharma PLC, a biopharmaceutical company focusing on peptide-based therapeutics, has announced its Annual General Meeting (AGM) to be held on June 28, 2024. Shareholders are informed that the AGM details and Annual Report for 2023 are available on the company’s website. The company specializes in developing treatments for autoimmune diseases, with its leading program, P140, showing promise for Lupus and other autoimmune disorders.
For further insights into GB:IMM stock, check out TipRanks’ Stock Analysis page.